The Clinical Relevance of Molecular Genetics in Soft Tissue Sarcomas

  title={The Clinical Relevance of Molecular Genetics in Soft Tissue Sarcomas},
  author={Jose Luis Ordo{\~n}ez and Daniel Osuna and Daniel J. Garc{\'i}a-Dom{\'i}nguez and Ana T. Amaral and Ana Pastora Otero-Motta and Carlos Mackintosh and Mar{\'i}a Victoria Sevillano and Mar{\'i}a Victoria Barbado and Teresa Hernández and Enrique de {\'A}lava},
  journal={Advances in Anatomic Pathology},
Bone and soft tissue sarcomas are an infrequent and heterogeneous group of mesenchymal tumors including more than a hundred different entities attending to histologic patterns. Research into the molecular aspects of sarcomas has increased greatly in the last few years. This enormous amount of knowledge has allowed, for instance, to refine the classification of sarcomas, improve the diagnosis, and increase the number of therapeutical targets available, most of them under preclinical evaluation… 

The role of molecular pathology in mediastinal sarcomas

The role of molecular pathology is covered, specifically with regards to diagnosis, as well as discuss the salient molecular genetic features of the various types of sarcoma that occur within the mediastinum.

Sarcomas Genetics: From Point Mutation to Complex Karyotype, from Diagnosis to Therapies

The next breakthrough toward a personalized medicine for sarcoma will be the identification of signature predicting drug response, the best being targetable oncogenic driver alteration.

Molecular pathology diagnostics in cutaneous mesenchymal tumors

The combined immunohistochemical and molecular genetic algorithm of Sarcoma diagnosis is shown in the context of dermatofibrosarcoma protuberans, malignant vascular tumors, epithelioid sarcoma, and clear cell sarcomas.

Innovative Therapies in Ewing Sarcoma

This review focuses on the research on targeted therapies in Ewing Sarcoma, and discussed some bottlenecks related to this such as the possible role of pathologists, the availability of samples, the lack of appropriate animal models, and the resources needed to carry out preclinical and clinical research.

Identification of Subtype-specific Pathogenetic Aberrations in Soft Tissue Sarcoma utilising High-resolution Genomic Copy Number Analysis

The utilisation of microarray-based comparative genomic hybridisation for high resolution mapping of genome-wide SCNA in order to identify patterns that are specific for three STS subtypes Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma and Gastrointestinal Stromal Tumours was utilised.

Molecular Genetics of Ewing Sarcoma

Targeting EWSR1-FLI1 by using RNA interference approaches reduced tumour growth and tumourigenicity of ES cells in vitro and in vivo and is a good tool in order to get knowledge in the ES biology.

Molecular Pathology of Soft-Tissue Neoplasms and Its Role in Clinical Practice.

Molecular pathology provides a unique opportunity for pathologists to play a crucial role in the multidisciplinary care of patients with sarcoma, with histological and immunohistochemical findings providing actionable information for the diagnosis, prognosis, and choice of therapeutic modality.

Molecular diagnostics of soft tissue tumors.

Cytogenetic and molecular genetic assays are used routinely for diagnostic purposes in soft tissue pathology and represent a powerful adjunct to complement conventional microscopy and clinicoradiographic evaluation in the formulation of an accurate diagnosis.

Molecular Pathology of Bone and Soft Tissue Neoplasms and Potential Targets for Novel Therapy

Bone and soft tissue tumors encompass a rare but a heterogenous group of mesenchymal neoplasms ranging from benign to malignant. Frequently, the diagnosis of many bone and soft tissue tumors prove to



Molecular pathology of sarcomas.

This review points out the clinical projection of sarcomagenesis elucidation and knowledge of diverse types of molecular alterations in sarcomas, as well as the identification of reliable molecular markers and possible therapeutic targets.

Targeting sarcomas: therapeutic targets and their rational.

More recent targeted therapy in sarcomas is described, with special emphasis on Ewing's sarcoma and the role of cancer stem cells (CSCs) and the relevance of reliable molecular markers and possible therapeutic targets.

Molecular prognostication for soft tissue sarcomas: are we ready yet?

The recent debate around the prognostic value of synovial sarcoma fusion genes is an example of many of the issues encountered in studies of molecular prognostic markers in cancer, and what valuable lessons can be taken from these studies.

Soft tissue sarcoma trials: one size no longer fits all.

  • J. Verweij
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
The data indicate not only that the disease may be drug-sensitive as a result of specific molecular changes, but also that the required drug dose may be dependent on specific changes within these molecular changes.

Pathology of soft‐tissue tumors: Daily diagnosis, molecular cytogenetics and experimental approach

The MMP upregulation mechanism mediated by tumor‐associated emmprin may be a potentially useful target in anti‐tumor invasion therapy for sarcomas, playing a crucial role in tumor progression, invasion and metastasis.

Synovial Sarcoma: From Genetics to Genetic-based Animal Modeling

The usefulness of genetics-based mouse models as a valuable research tool in the hunt for key molecular determinants of this lethal disease as well as a preclinical platform for designing and evaluating novel treatment strategies are discussed.

Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene

Taken together, the results indicate that virtually all LGFMS are characterized by a chimeric FUS/CREB3L2 gene, and that rare cases may display a variant F US/CREb3L1 fusion.

SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.

The type of SYT-SSX fusion transcript correlates with both the histologic subtype and the clinical behavior of synovial sarcoma and may also yield important independent prognostic information.

Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor.

DSRCT represents the third primitive sarcoma in which the EWS gene is involved and the first instance of recurrent rearrangement of a tumor suppressor gene, WT1, in a specific tumor type.